{"id":"capecitabine-during-all-radiotherapy-period","safety":{"commonSideEffects":[{"rate":"27%","effect":"Hand-foot syndrome"},{"rate":"21%","effect":"Diarrhea"},{"rate":"20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Capecitabine is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which then inhibits thymidylate synthase, an enzyme involved in DNA synthesis.","oneSentence":"Capecitabine is a thymidylate synthase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:51.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT06931808","phase":"PHASE4","title":"Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-03-01","conditions":"Localized Advanced Rectal Adenocarcinoma","enrollment":20},{"nctId":"NCT01515787","phase":"PHASE2, PHASE3","title":"PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-06-12","conditions":"Colorectal Cancer","enrollment":1194},{"nctId":"NCT00565487","phase":"PHASE1","title":"Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2007-12","conditions":"Pancreatic Cancer","enrollment":15},{"nctId":"NCT00909987","phase":"PHASE2","title":"Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2009-03","conditions":"Rectum Cancer","enrollment":46},{"nctId":"NCT00808379","phase":"PHASE2","title":"Concurrent Chemo-Radiotherapy Versus Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers","status":"UNKNOWN","sponsor":"Tata Memorial Hospital","startDate":"2006-05","conditions":"Rectal Cancer","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xeloda"],"phase":"phase_2","status":"active","brandName":"Capecitabine during all Radiotherapy period","genericName":"Capecitabine during all Radiotherapy period","companyName":"Grupo Espanol Multidisciplinario del Cancer Digestivo","companyId":"grupo-espanol-multidisciplinario-del-cancer-digestivo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a thymidylate synthase inhibitor. Used for Colorectal cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}